Daniel Grosslight
Stock Analyst at Citigroup
(1.29)
# 3,705
Out of 5,139 analysts
114
Total ratings
38.03%
Success rate
-11.71%
Average return
Main Sectors:
Stocks Rated by Daniel Grosslight
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAY Waystar Holding | Maintains: Buy | $49 → $46 | $30.27 | +51.97% | 3 | Jan 9, 2026 | |
| TDOC Teladoc Health | Maintains: Neutral | $10 → $9 | $6.28 | +43.31% | 13 | Jan 9, 2026 | |
| PHR Phreesia | Maintains: Buy | $29 → $25 | $16.39 | +52.53% | 8 | Jan 9, 2026 | |
| HCAT Health Catalyst | Maintains: Neutral | $3.25 → $2.75 | $2.31 | +19.05% | 12 | Jan 9, 2026 | |
| GDRX GoodRx Holdings | Maintains: Buy | $5 → $4.5 | $2.68 | +67.91% | 8 | Jan 9, 2026 | |
| EVH Evolent Health | Maintains: Buy | $9.5 → $6 | $3.77 | +59.15% | 6 | Jan 9, 2026 | |
| CTEV Claritev | Maintains: Buy | $80 → $63 | $30.44 | +106.96% | 4 | Jan 9, 2026 | |
| ACH Accendra Health | Maintains: Buy | $7 → $4 | $2.52 | +58.73% | 1 | Jan 9, 2026 | |
| CAH Cardinal Health | Upgrades: Buy | $190 → $244 | $212.45 | +14.85% | 11 | Jan 9, 2026 | |
| MCK McKesson | Maintains: Buy | $820 → $860 | $840.46 | +2.32% | 8 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 → $1 | $1.02 | -1.96% | 6 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $25 → $30 | $31.38 | -4.40% | 11 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $23.33 | +7.16% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $10 | $3.66 | +173.22% | 7 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $8 | $11.42 | -29.95% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.25 | $1.61 | -22.36% | 5 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $7 → $3.5 | $3.96 | -11.62% | 2 | Nov 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $10.61 | +22.53% | 1 | Dec 11, 2019 |
Waystar Holding
Jan 9, 2026
Maintains: Buy
Price Target: $49 → $46
Current: $30.27
Upside: +51.97%
Teladoc Health
Jan 9, 2026
Maintains: Neutral
Price Target: $10 → $9
Current: $6.28
Upside: +43.31%
Phreesia
Jan 9, 2026
Maintains: Buy
Price Target: $29 → $25
Current: $16.39
Upside: +52.53%
Health Catalyst
Jan 9, 2026
Maintains: Neutral
Price Target: $3.25 → $2.75
Current: $2.31
Upside: +19.05%
GoodRx Holdings
Jan 9, 2026
Maintains: Buy
Price Target: $5 → $4.5
Current: $2.68
Upside: +67.91%
Evolent Health
Jan 9, 2026
Maintains: Buy
Price Target: $9.5 → $6
Current: $3.77
Upside: +59.15%
Claritev
Jan 9, 2026
Maintains: Buy
Price Target: $80 → $63
Current: $30.44
Upside: +106.96%
Accendra Health
Jan 9, 2026
Maintains: Buy
Price Target: $7 → $4
Current: $2.52
Upside: +58.73%
Cardinal Health
Jan 9, 2026
Upgrades: Buy
Price Target: $190 → $244
Current: $212.45
Upside: +14.85%
McKesson
Sep 24, 2025
Maintains: Buy
Price Target: $820 → $860
Current: $840.46
Upside: +2.32%
Aug 6, 2025
Downgrades: Neutral
Price Target: $3 → $1
Current: $1.02
Upside: -1.96%
May 6, 2025
Maintains: Sell
Price Target: $25 → $30
Current: $31.38
Upside: -4.40%
Apr 22, 2024
Initiates: Buy
Price Target: $25
Current: $23.33
Upside: +7.16%
Aug 9, 2023
Maintains: Neutral
Price Target: $9 → $10
Current: $3.66
Upside: +173.22%
Aug 4, 2023
Downgrades: Sell
Price Target: $7 → $8
Current: $11.42
Upside: -29.95%
Apr 28, 2023
Maintains: Neutral
Price Target: $1.5 → $1.25
Current: $1.61
Upside: -22.36%
Nov 16, 2021
Downgrades: Neutral
Price Target: $7 → $3.5
Current: $3.96
Upside: -11.62%
Dec 11, 2019
Initiates: Outperform
Price Target: $13
Current: $10.61
Upside: +22.53%